Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Anti-CD20 treatment for B-cell malignancies: current status and future directions

“…blinatumomab [196], the CD20-TDB [T-cell-dependent bispecific antibody] mosunetuzumab [197,198] and the obinutuzumab-based CD20-TCB glofitamab [199]), and a mAb for CD19, tafasitamab (MOR208), which has shown promising activity as a single agent in patients with R/R DLBCL, MCL, FL, or other iNHL [200]. Tafasitamab is now being investigated further in DLBCL as a combination with lenalidomide in the single-arm Phase 2 L-MIND study in 81 patients [201,202], or with bendamustine in comparison with rituximab-bendamustine in the Phase 2/3 B-MIND study with an enrollment target of 330 [203]. [204,205] and tisagenlecleucel [206,207], while a further agent, lisocabtagene maraleucel, is in clinical trials [208].…”

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

“…Moreover, in vitro studies suggested that lenalidomide can further enhance the ADCC effects of tafasitamab, and the combination with lenalidomide resulted in a high response rate of relapsed and refractory DLBCL patients. [ 136 ]. Tafasitamab has been granted accelerated FDA approval in combination with lenalidomide for patients with relapsed DLBCL.…”

Two Retrospective Analyses Show No Associated Adverse Outcomes With Delayed RP

“…Please see accompanying brief summary of full Prescribing Information. (14) in the full prescribing information]. • Diphenhydramine 25 mg to 50 mg orally or intravenously (or equivalent).…”

“…3 , absolute neutrophil count ≥1 × 10 9 /L, creatinine clearance ≥30 mL/min (MDRD formula), and AST and/ or ALT ≤3 × ULN. Patients received SARCLISA 10 mg/kg intravenously, weekly in the first cycle and every two weeks thereafter, in combination with pomalidomide and low dose dexamethasone (Isa-Pd) (n=152) or pomalidomide and low dose dexamethasone (Pd) (n=149) [see Clinical Studies (14) in the full prescribing information]. Among patients receiving Isa-Pd, 66% were exposed to SARCLISA for 6 months or longer and 24% were exposed for greater than 12 months or longer.…”

“…The National Comprehensive Cancer Network has developed guidelines for the identification and management of distress, defined as "a multifactorial, unpleasant experience of a psychological (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, its physical symptoms, and its treatment." 14 An estimated 20% to 52% of individuals with cancer struggle with distress, 15-17 and about one-third meet clinical criteria for depression. 18 Negative psychological states not only impact overall quality of life in those with cancer, but may also impact overall health.…”